The Diabeo software enabling individualized insulin dose adjustments combined with telemedicine support improves HbA1c in poorly controlled type 1 diabetic patients: a 6-month, randomized, open-label, parallel-group, multicenter trial (TeleDiab 1 Study).

Guillaume Charpentier 1, * Pierre-Yves Benhamou 2 Dured Dardari 1 Annie Clergeot 3 Sylvia Franc 1 Pauline Schaepelynck-Belicar 4 Bogdan Catargi 5 Vincent Melki 6 Lucy Chaillous 7 Anne Farret 8 Jean-Luc Bosson 9 Alfred Penfornis 3
* Auteur correspondant
1 CERITD - Service de diabétologie
2 Service d'Endocrinologie, Pôle Digidune
3 Service de diabétologie - endocrinologie [Besançon]
4 Endocrinologie
5 Service d'endocrinologie
6 Service de diabétologie
7 Clinique d'Endocrinologie, Maladies Métaboliques et Nutrition
8 Service d'endocrinologie
9 CIC- Grenoble
Abstract : OBJECTIVE: To demonstrate that Diabeo software enabling individualized insulin dose adjustments combined with telemedicine support significantly improves HbA(1c) in poorly controlled type 1 diabetic patients. RESEARCH DESIGN AND METHODS: In a six-month open-label parallel-group, multicenter study, adult patients (n = 180) with type 1 diabetes (>1 year), on a basal-bolus insulin regimen (>6 months), with HbA(1c) ≥ 8%, were randomized to usual quarterly follow-up (G1), home use of a smartphone recommending insulin doses with quarterly visits (G2), or use of the smartphone with short teleconsultations every 2 weeks but no visit until point end (G3). RESULTS: Six-month mean HbA(1c) in G3 (8.41 ± 1.04%) was lower than in G1 (9.10 ± 1.16%; P = 0.0019). G2 displayed intermediate results (8.63 ± 1.07%). The Diabeo system gave a 0.91% (0.60; 1.21) improvement in HbA(1c) over controls and a 0.67% (0.35; 0.99) reduction when used without teleconsultation. There was no difference in the frequency of hypoglycemic episodes or in medical time spent for hospital or telephone consultations. However, patients in G1 and G2 spent nearly 5 h more than G3 patients attending hospital visits. CONCLUSIONS: The Diabeo system gives a substantial improvement to metabolic control in chronic, poorly controlled type 1 diabetic patients without requiring more medical time and at a lower overall cost for the patient than usual care.
Type de document :
Article dans une revue
Diabetes Care, American Diabetes Association, 2011, 34 (3), pp.533-9. 〈10.2337/dc10-1259〉
Liste complète des métadonnées
http://www.hal.inserm.fr/inserm-00628821
Contributeur : Sarah Hamant <>
Soumis le : mardi 4 octobre 2011 - 11:54:02
Dernière modification le : lundi 10 septembre 2018 - 15:38:57

Lien texte intégral

openaccess

Identifiants

Collections

UNIV-FCOMTE

Citation

Guillaume Charpentier, Pierre-Yves Benhamou, Dured Dardari, Annie Clergeot, Sylvia Franc, et al.. The Diabeo software enabling individualized insulin dose adjustments combined with telemedicine support improves HbA1c in poorly controlled type 1 diabetic patients: a 6-month, randomized, open-label, parallel-group, multicenter trial (TeleDiab 1 Study).. Diabetes Care, American Diabetes Association, 2011, 34 (3), pp.533-9. 〈10.2337/dc10-1259〉. 〈inserm-00628821〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

277

Contact

support.ccsd.cnrs.fr
hal.support@ccsd.cnrs.fr
Logo CCSD